LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

87.62 1.06

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

84.23

Максимум

88.32

Ключови измерители
By Trading Economics
Приходи	-8.1M -56M
Продажби	2.9M 60M
EPS	-0.83
Марж на печалбата	-92.559
Служители	414
EBITDA	-9.7M -52M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+58.5% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	124M 6B
Предишно отваряне	86.56
Предишно затваряне	87.62

Настроения в новините

By Acuity

100%

326 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.05.2026 г., 23:10 ч. UTC

Горещи акции

Stocks to Watch: Agilysys, XP

18.05.2026 г., 18:44 ч. UTC

Значими двигатели на пазара

Claritev Shares Recover After Comments About DOJ

18.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Earnings' Last Gasp -- Barrons.com

18.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

18.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18.05.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

18.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

18.05.2026 г., 20:25 ч. UTC

Печалби

Correct: XP 1Q Total Client Assets BRL1.53T

18.05.2026 г., 20:23 ч. UTC

Печалби

XP 1Q Total Client Assets BRL1.53B

18.05.2026 г., 20:19 ч. UTC

Печалби

XP 1Q Adj EPS BRL2.49 >XP

18.05.2026 г., 20:19 ч. UTC

Печалби

XP 1Q Rev BRL4.73B >XP

18.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18.05.2026 г., 19:00 ч. UTC

Печалби

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18.05.2026 г., 18:52 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18.05.2026 г., 18:17 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18.05.2026 г., 17:22 ч. UTC

Пазарно говорене

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18.05.2026 г., 16:57 ч. UTC

Придобивния, сливания и поглъщания

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18.05.2026 г., 16:57 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

18.05.2026 г., 16:57 ч. UTC

Пазарно говорене

Commodities Higher as Traders Want Physical Assets -- Market Talk

18.05.2026 г., 16:54 ч. UTC

Придобивния, сливания и поглъщания

Vinci Doesn't Set Out Financial Details of Deal

18.05.2026 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18.05.2026 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18.05.2026 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18.05.2026 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Vinci Buys Canada's Modern Group of Companies

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

58.5% нагоре

12-месечна прогноза

Среден 137.64 USD 58.5%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

326 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.